BPON-04 Injection
创建时间：2022-05-16 14:19
|
Name/Code number |
BPON-04 Injection |
|
Category |
New Chemical Entity |
|
Mode of Action (MOA) |
GABAA receptor agonist |
|
Formulation |
Lyophilized powder for injection |
|
Strengths |
TBD |
|
Indication |
Intravenous general anesthesia |
|
Stage |
Preclinical |
|
Characteristics/Advantages |
1.As a derivative of Remimazolam, BPON-04 can easily penetrate into blood-brain barrier, which results in faster and better efficacy than that of Remimazolam
2.BPON-04 showed shorter anesthetic duration and recovery time than those of Remimazolam, because it can be metabolized faster in vivo
3.Different from Remimazolam, BPON-04 will neither generate formaldehyde in vivo nor produce genotoxic impurity (sulfonate), which means its lower side effects than that of Remimazolam
4.A great potential to replace Remimazolam in intravenous general anesthesia
5.Global IP protection (Authorized US, EP and CN patents)
|
|
Cooperation Model |
Out-license for global market outside of China (China right has been out-licensed) |
